FDA Approves Rybrevant Plus Chemo for Front-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
Regulatory action makes Rybrevant plus chemotherapy the first FDA-approved therapy for the first-line treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations.
